Press releases
- Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
- Pulse Biosciences Enhances Executive Leadership Team
- Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
- Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
- Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
- Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
- Pulse Biosciences Announces Plans to Initiate a Rights Offering
- Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.10 |
---|---|
High | 12.10 |
Low | 12.10 |
Bid | 12.10 |
Offer | 12.40 |
Previous close | 11.00 |
Average volume | 1.67 |
---|---|
Shares outstanding | 55.23m |
Free float | 16.36m |
P/E (TTM) | -- |
Market cap | 735.60m USD |
EPS (TTM) | -0.8152 USD |
Data delayed at least 15 minutes, as of May 29 2024 08:31 BST.
More ▼